Leveraging on its proprietary technology, Alia Therapeutics, the first Italian CRISPR company, is developing new therapeutic approaches to treat genetic diseases once considered incurable. Alia’s unique CRISPR-based genome editing tools allow unprecedented specificity in modifying the genome, coupled with safe and efficient delivery into target cells.